GlassScriptPhysician profile
Alan W Chang
NPI 1912992330
$12,943.35
in general payments reported to CMS, 2019-2025
50 companies · $552 in 2025
The $552 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,764 · 2020: $994 · 2021: $1,962 · 2022: $1,912 · 2023: $2,395 · 2024: $3,365 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,251 · Education: $60.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,250.87 |
| Education | $60.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,703.49 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,320.14 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $879.04 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $836.45 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $719.76 | 2021-2023 | Zeposia |
| Celgene Corporation | $561.68 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $467.58 | 2019-2024 | Livdelzi |
| Ardelyx, INC. | $459.33 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $428.16 | 2019-2024 | Linzess |
| Pfizer INC. | $413.71 | 2019-2024 | |
| Genzyme Corporation | $357.82 | 2022-2025 | |
| Shionogi INC | $344.98 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $332.62 | 2019-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $306.15 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $272.41 | 2019-2025 | Suflave |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $252.70 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $209.20 | 2019-2024 | Zinplava, Dificid, Zerbaxa |
| Medtronic, INC. | $202.90 | 2024-2025 | Interstim, Pillcam |
| Lilly USA, LLC | $188.18 | 2024 | Omvoh |
| Daiichi Sankyo INC. | $184.33 | 2019-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $179.49 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $158.56 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $125.67 | 2024-2025 | Iqirvo, Bylvay |
| Thd America, INC. | $124.23 | 2022 | |
| Redhill Biopharma INC. | $106.21 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Qol Medical, LLC | $98.24 | 2021-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $68.76 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $58.50 | 2021 | |
| Ucb, INC. | $58.38 | 2019-2020 | |
| Amgen INC. | $50.62 | 2021 | |
| Allergan, INC. | $47.03 | 2019-2020 | |
| Boston Scientific Corporation | $44.31 | 2024 | Wavewriter Alpha Prime 16 |
| Fresenius Kabi USA, LLC | $39.28 | 2023-2024 | Idacio |
| Vivus LLC | $36.06 | 2019 | |
| Digestive Care, INC. | $33.34 | 2023-2024 | Pertzye |
| Sandoz INC. | $32.96 | 2024 | Hyrimoz |
| Blueprint Medicines Corporation | $31.32 | 2023 | |
| Madrigal Pharmaceuticals | $25.08 | 2024 | Resmetirom |
| Lexicon Pharmaceuticals, INC. | $22.86 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.95 | 2021 | |
| Organon LLC | $18.52 | 2023 | Renflexis |
| Alnylam Pharmaceuticals INC. | $18.28 | 2024 | Givlaari |
| Cook Medical LLC | $17.11 | 2021 | |
| Pharmacosmos Therapeutics INC. | $16.94 | 2022 | |
| Teleflex LLC | $15.90 | 2024 | Solesta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.01 | 2023 | Cyltezo |
| Intra-Sana Laboratories | $14.32 | 2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Concordia Pharmaceuticals INC. | $14.31 | 2019 | |
| Shire North American Group INC | $12.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.